Bio-Rad Laboratories Files 8-K
Ticker: BIO-B · Form: 8-K · Filed: Aug 26, 2025 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
Related Tickers: BIO
TL;DR
BIO files 8-K, standard disclosure, no major news.
AI Summary
Bio-Rad Laboratories, Inc. filed an 8-K on August 26, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for the date.
Why It Matters
This 8-K filing serves as a routine disclosure for Bio-Rad Laboratories, Inc., indicating updates or filings related to financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no indication of significant new risks or material adverse events.
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — Registrant
- August 26, 2025 (date) — Date of Report
- 1000 Alfred Nobel Dr. Hercules , California 94547 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Bio-Rad Laboratories, Inc.?
The primary purpose is to report information under Regulation FD and to file financial statements and exhibits as of August 26, 2025.
What is the exact date of the report for Bio-Rad Laboratories, Inc.?
The date of the report is August 26, 2025.
What is the Commission File Number for Bio-Rad Laboratories, Inc.?
The Commission File Number is 1-07928.
Where are Bio-Rad Laboratories, Inc.'s principal executive offices located?
The principal executive offices are located at 1000 Alfred Nobel Dr. Hercules, California 94547.
Does this 8-K filing disclose any specific new financial results or material events?
Based on the provided text, this 8-K filing is for Regulation FD disclosure and financial statements/exhibits, and does not detail specific new financial results or material events.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-08-26 09:00:36
Key Financial Figures
- $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Filing Documents
- bio-20250826.htm (8-K) — 34KB
- dropletdigitalpcrpresent.htm (EX-99.1) — 15KB
- dropletdigitalpcrpresent001.jpg (GRAPHIC) — 53KB
- dropletdigitalpcrpresent002.jpg (GRAPHIC) — 241KB
- dropletdigitalpcrpresent003.jpg (GRAPHIC) — 47KB
- dropletdigitalpcrpresent004.jpg (GRAPHIC) — 109KB
- dropletdigitalpcrpresent005.jpg (GRAPHIC) — 120KB
- dropletdigitalpcrpresent006.jpg (GRAPHIC) — 107KB
- dropletdigitalpcrpresent007.jpg (GRAPHIC) — 108KB
- dropletdigitalpcrpresent008.jpg (GRAPHIC) — 81KB
- dropletdigitalpcrpresent009.jpg (GRAPHIC) — 82KB
- dropletdigitalpcrpresent010.jpg (GRAPHIC) — 100KB
- dropletdigitalpcrpresent011.jpg (GRAPHIC) — 108KB
- dropletdigitalpcrpresent012.jpg (GRAPHIC) — 89KB
- dropletdigitalpcrpresent013.jpg (GRAPHIC) — 110KB
- dropletdigitalpcrpresent014.jpg (GRAPHIC) — 88KB
- dropletdigitalpcrpresent015.jpg (GRAPHIC) — 79KB
- dropletdigitalpcrpresent016.jpg (GRAPHIC) — 106KB
- dropletdigitalpcrpresent017.jpg (GRAPHIC) — 35KB
- dropletdigitalpcrpresent018.jpg (GRAPHIC) — 72KB
- 0000012208-25-000054.txt ( ) — 2599KB
- bio-20250826.xsd (EX-101.SCH) — 2KB
- bio-20250826_def.xml (EX-101.DEF) — 15KB
- bio-20250826_lab.xml (EX-101.LAB) — 27KB
- bio-20250826_pre.xml (EX-101.PRE) — 16KB
- bio-20250826_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. As previously announced, Bio-Rad Laboratories, Inc. (the "Company") plans to host an informational webinar on Bio-Rad's Droplet Digital PCR (ddPCR) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by the Company's President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast of the event will be available in the "Investor Relations" section of the Company's website under "Events & Presentations" at investors.bio-rad.com. On August 26, 2025, the Company posted the informational webinar's accompanying slide presentation on the "Investor Relations" section of its website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast and the accompanying slide presentation will be available for up to a year. A copy of the informational webinar's accompanying slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Droplet Digital PCR Presentation dated August 26, 2025 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: August 26, 2025 By: /s/ Courtney C. Enloe Courtney C. Enloe Executive Vice President, General Counsel & Secretary